Similar articles

• Lenalidomide for bortezomib-resistant multiple myeloma.

  Briani C, Berno T, Campagnolo M, Zambello R. Briani C, et al. Nat Rev Clin Oncol. 2010 Sep;7(9). doi: 10.1038/nrclinonc.2010.31-c1. Nat Rev Clin Oncol. 2010. PMID: 20824906 No abstract available.
• New treatments in multiple myeloma: beyond optimal treatment.

  Harousseau JL. Harousseau JL. Ann Oncol. 2008 Jul;19 Suppl 5:v68-70. doi: 10.1093/annonc/mdn314. Ann Oncol. 2008. PMID: 18611904 No abstract available.
• [Molecular-targeted therapy of multiple myeloma].

  Iida S. Iida S. Nihon Naika Gakkai Zasshi. 2010 Jan 10;99(1):132-9. doi: 10.2169/naika.99.142. Nihon Naika Gakkai Zasshi. 2010. PMID: 20376958 Review. Japanese. No abstract available.
• Thalidomide, lenalidomide and bortezomib in the management of newly diagnosed multiple myeloma.

  Laubach JP, Schlossman RL, Mitsiades CS, Anderson KC, Richardson PG. Laubach JP, et al. Expert Rev Hematol. 2011 Feb;4(1):51-60. doi: 10.1586/ehm.10.83. Expert Rev Hematol. 2011. PMID: 21322778 Review.
• Lenalidomide efficacy in bortezomib-resistant myeloma.

  Gozzetti A, Crupi R, Defina M, Bocchia M. Gozzetti A, et al. Nat Rev Clin Oncol. 2010 Sep;7(9). doi: 10.1038/nrclinonc.2010.31-c2. Nat Rev Clin Oncol. 2010. PMID: 20824907 No abstract available.